Pharmaceutical packaging is increasingly becoming part of the drug development process as Contract Development and Manufacturing Organizations (CDMOs) expand their capabilities beyond manufacturing.
Growing investments in sterile fill-finish, drug-device combinations, prefilled syringes, cartridges and packaging are encouraging closer integration between drug development, manufacturing and packaging.
This shift means packaging decisions are being considered earlier in the product lifecycle, particularly for complex and regulated products where material performance, usability, compliance, traceability and supply-chain reliability are critical.
For packaging suppliers, the trend creates an opportunity to engage earlier with pharma companies and CDMOs and offer specialized, value-added solutions rather than competing only on price.
The message for the packaging industry is clear: packaging is moving from the end of the pharmaceutical development process closer to the beginning.